Skip to main content
. 2022 Jan 25;12:760013. doi: 10.3389/fphar.2021.760013

TABLE 2.

Description of ADR reports of mAbs vs. non-mAbs.

Characteristic mAbs N = 575 (%) Non-mAb N = 15,335 (%) p value a
Mean age ± SD Age groups (years) 57.94 ± 13.72 57.61 ± 14.28 0.841 b
 0–5 3 (0.52) 193 (1.26) <0.001
 6–17 4 (0.70) 231 (1.51)
 18–34 26 (4.52) 422 (2.75)
 35–59 265 (46.09) 6,685 (43.59)
 60–79 254 (44.17) 7,452 (48.59)
 ≥80 23 (4.00) 308 (2.01)
Sex
 Female 328 (57.04) 8,363 (54.54) 0.244
 Male 247 (42.96) 6,959 (45.38)
Year
 2016 6 (1.04) 1,398 (9.12) <0.001
 2017 19 (3.30) 1834 (11.96)
 2018 33 (5.74) 2,455 (16.01)
 2019 140 (24.35) 3,865 (25.20)
 2020 377 (65.57) 5,783 (37.71)
Disease types
 Single 508 (88.35) 13,539 (88.29) 0.965
 Multiple 67 (11.65) 1796 (11.71)
Polypharmacy
 Polypharmacy 37 (6.43) 940 (6.13) 0.765
 Non-polypharmacy 538 (93.57) 14,395 (93.87)
Past history of ADRs
 No 549 (95.48) 14,279 (93.11) 0.027
 Yes 26 (4.52) 1,056 (6.89)
a

Chi-squared test.

b

T test.